Placebo – Communicable Diseases Research

Effect of oral antiseptics in reducing SARS-CoV-2 infectivity: evidence from a randomized double-blind clinical trial

Randomized Controlled Trial

Published on 2022-12-012022-10-05
Journal: Emerging Microbes & Infections
[Category] COVID19(2023년), SARS, 임상,

Immunogenicity and safety of BNT162b2 mRNA vaccine in Chinese adults: A phase 2 randomised clinical trial

Article

Published on 2022-12-012022-10-06
Journal: The Lancet Regional Health - Western Pacific
[Category] 진단,

[키워드] acute respiratory syndrome Administered Adults adverse event AEs age analysis assessment assigned BNT162b2 BNT162b2 mRNA BNT162b2 mRNA vaccine China Chinese clinical trial Complete Completed conducted coronavirus COVID-19 development dose double-blind Efficacy and safety enrolled Follow-up geometric mean titer GMT GMTs Han Chinese healthy immune response immunogenicity immunogenicity endpoint Inc independent individual injection intramuscular Intramuscular injection investigators Laboratory parameters management messenger Messenger RNA Mild moderate mRNA vaccine Neutralising Antibodies neutralising antibody of BNT162b2 participant Participants pharmaceutical Placebo placebo-controlled trial randomisation randomised Randomly reactogenicity receive recipients recruited reduced remained reported resolved Result robust Safety SARS-CoV-2 SARS-CoV-2 variant SCR second dose sera serious AE seroconversion rate severity Shanghai Sponsor statisticians stratified T-cell Response the placebo group Tolerability Treatment Trial utilised vaccination vaccination. vaccine administration were blinded
[DOI] 10.1016/j.lanwpc.2022.100586 PMC 바로가기 [Article Type] Article

Preclinical assessment and randomized Phase I study of CT-P63, a broadly neutralizing antibody targeting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)

Article

Published on 2022-12-012022-11-15
Journal: Emerging Microbes & Infections
[Category] COVID19(2023년), SARS, 변종, 비임상, 진단, 치료기술, 치료제,

[키워드] acute respiratory syndrome Beta Blood caused clinically Concentration coronavirus COVID-19 creatine phosphokinase CT-P63 deaths declining Delta demonstrated detectable dose double-blind evaluated groups healthy volunteer Immunity in vitro in vivo Infection Infectious virus lung monoclonal monoclonal antibody morbidity and mortality mutated variant Neutralizing Neutralizing activity neutralizing antibody neutralizing antibody. omicron pandemic parallel-group participant peaked phase Placebo placebo-controlled Preclinical prevalent Prophylactic Randomized reduced respiratory tract Safe SARS-CoV-2 SARS-CoV-2 variant SARS-CoV-2 variants of concern Serious Adverse Events significantly single ascending dose study drug TEAE titre Tolerability Transgenic mouse treated Treatment treatment-emergent adverse event vaccination variants variants of SARS-CoV-2 wild-type
[DOI] 10.1080/22221751.2022.2117094 PMC 바로가기

Effect of colchicine on the outcomes of patients with COVID-19: a systematic review and meta-analysis of randomised controlled trials

COVID-19 환자의 결과에 대한 콜히친의 영향: 무작위 대조 시험의 체계적인 검토 및 메타 분석

Meta-Analysis

Published on 2022-12-012022-09-11
Journal: Annals of Medicine
[Category] 임상,

[키워드] 95% CI addition adverse event adverse events Clinical efficacy clinical outcomes ClinicalTrials Cochrane Library Colchicine control group COVID-19 database diarrhoea Effect higher risk hospital Hospital stay improve clinical outcome mean difference mechanical ventilation Meta-analysis Mortality no significant difference non-invasive ventilation non-invasive ventilation. not reduce Odds ratio outcome OVID Patient patients with COVID-19 Placebo placebos randomised controlled trial RCT RCTs receiving risk SARS-CoV-2 searched significant difference significantly higher standard treatment study group Support systematic review the study group Treatment Web of Science
[DOI] 10.1080/07853890.2022.2096919 PMC 바로가기 [Article Type] Meta-Analysis

Efficacy of heterologous boosting against SARS-CoV-2 using a recombinant interferon-armed fusion protein vaccine (V-01): a randomized, double-blind and placebo-controlled phase III trial

재조합 인터페론 무장 융합 단백질 백신(V-01)을 사용한 SARS-CoV-2에 대한 이종 부스팅의 효능: 무작위, 이중 맹검 및 위약 대조 3상 시험

Clinical Trial

Published on 2022-12-012022-09-11
Journal: Emerging Microbes & Infections
[Category] COVID19(2023년), SARS, 변종, 임상, 진단,

[키워드] adverse event antibody assigned booster clinical trial common adverse event conducted COVID-19 vaccine COVID-19 vaccines dose double-blind dramatic increase Efficacy elicit eligible fatigue Fever fusion protein groups headache healthy Heterologous heterologous boosting Humoral immunity Identifier Immunity inactivated Inactivated vaccine Inactivated Vaccines Inc injection injection site intention-to-treat principle Malaysia Mild-to-moderate Neutralizing Neutralizing antibodies occurred Older omicron Omicron variant over Pain participant Participants Placebo placebo-controlled primary endpoint Randomized Randomly receive regimen robust Safe SARS-CoV-2 SARS-COV-2 infection second dose Serious Adverse Events subunit Subunit vaccine Subunit vaccine. Surveillance symptomatic SARS-CoV-2 infection the epidemic titre Trial Trial registration V-01 Vaccine vaccine efficacy variant virus-neutralizing antibodies was measured were assessed
[DOI] 10.1080/22221751.2022.2088406 PMC 바로가기 [Article Type] Clinical Trial

Randomized, double-blind, placebo-controlled, crossover trial of oral doxycycline for epistaxis in hereditary hemorrhagic telangiectasia

Article

Published on 2022-11-072022-11-16
Journal: Orphanet Journal of Rare Diseases
[Category] 유전자 메커니즘,

[키워드] analysis Angiogenesis assigned Biomarkers bleeding Blood center double-blind doxycycline Effectiveness ENG Epistaxis Frequency heart failure help hemorrhage Hemorrhagic Hereditary Hereditary hemorrhagic telangiectasia Hereditary hemorrhagic telangiectasia. HHT IL-6 Inflammatory intravenous limitations Liver disease malformation marker mechanism Michael morbidity no significant difference not significantly different observation pathway Patient Placebo placebo-controlled provided Quality of life Randomized controlled trial Randomly RBC recruited Registered Registration secondary significantly higher stroke telangiectasia therapy Toronto Treatment treatment period Trial VEGF
[DOI] 10.1186/s13023-022-02539-8 PMC 바로가기

Efficacy and safety of Treamid in the rehabilitation of patients after COVID-19 pneumonia: a phase 2, randomized, double-blind, placebo-controlled trial

Article

Published on 2022-11-032022-11-16
Journal: Journal of Translational Medicine
[Category] 비임상,

[키워드] 1:1 Administered administration adverse event age Analysis animal model Anti-inflammatory assigned baseline Borg change changes in Chronic diseases clinical trial clinically COVID COVID pneumonia COVID-19 defined Diagnosis discharged double-blind Dyspnea Effect effective Efficacy Endpoint enrolled evaluated female female gender FEV first symptom FVC impairment increase in indicated Infection initial LLC lung damage Lung fibrosis Lung function Lungs mMRC moderate NCT04527354 offer past medical history Patient patients pharmacological treatment Placebo placebo group placebo-controlled clinical trial placebo-controlled trial Post-COVID rehabilitation predicted Prevent Primary outcome proportion pulmonary dysfunction pulmonary fibrosis Pulmonary function questionnaire Randomized Randomly reduction in Registered rehabilitation risk factor Russia SARS-CoV-2 secondary shown significant decrease significant difference stratified Support Symptoms Tolerability Treamid. Treatment Trial was done women
[DOI] 10.1186/s12967-022-03660-9 PMC 바로가기

Evaluation of mRNA-1273 Vaccine in Children 6 Months to 5 Years of Age

Article

Published on 2022-11-032022-11-15
Journal: The New England Journal of Medicine
[Category] Fulltext, MERS, 변종, 진단,

[키워드] 95% CI 95% confidence interval acute respiratory syndrome Administered administration Adults Adverse age assigned authority B.1.1.529 children circulating Cohort cohorts coronavirus coronavirus disease criteria determine development dose duration of follow-up Efficacy elicited evaluate evaluated event geometric mean concentration immune response incidence Infection injection median Month mRNA-1273 mRNA-1273 vaccine neutralizing antibody observer-blinded open label Part phase 3 trial Placebo placebo-controlled predominant Randomly reactogenicity receive Safe Secondary objective selected the vaccine Trial Vaccine variant Year
[DOI] 10.1056/NEJMoa2209367 PMC 바로가기

Efficacy and safety of nitazoxanide in treating SARS-CoV-2 infection: a systematic review and meta-analysis of blinded, placebo-controlled, randomized clinical trials

Article

Published on 2022-11-012022-11-15
Journal: European Journal of Clinical Pharmacology
[Category] SARS, 치료제,

[키워드] 95% CI 95% confidence interval addition anti-inflammatory effect antiparasitic antiviral activity blinded clinical benefit continuous variable COVID-19 D-dimer D-dimer level death dichotomous variable Disease progression Effect effect size Efficacy and safety element eligibility enrolled Evidence Frequency ICU admission in vitro individual Inflammation Invasive mechanical ventilation lactate dehydrogenase LDH magnitude Meta-analysis Mild moderate Moderate COVID-19 nitazoxanide no difference Patient patients peer-reviewed performed Placebo placebo-controlled positive positive RT-PCR Primary outcome randomized clinical trial RCT RCTs receiving reducing reduction in reported risk SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 infection. secondary outcome serum biomarker SMD standardized mean difference systematic review tested to define treat treated Viral load WBC were used White blood cell with COVID-19
[DOI] 10.1007/s00228-022-03380-5 PMC 바로가기

Efficacy of antiseptic mouthrinses against SARS-CoV-2: A prospective randomized placebo-controlled pilot study

Article

Published on 2022-11-012022-11-15
Journal: American journal of otolaryngology
[Category] COVID19(2023년), SARS, 치료기술, 치료제,